• Core US patent granted in world’s largest pharmaceutical market
• The patent provides a method of composition and method of use protection to 2036
Sydney, Australia, 14 January 2020:
Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced it has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for Patent Application 15/316868 (granted patent no. 10,532,090) which protects its HER-Vaxx cancer immunotherapy, currently in Phase II development for HER-2+ gastric cancer.
The patent titled “A vaccine composition and uses thereof’ protects the method of composition and method of use of Imugene’s HER-Vaxx for the generation of a therapeutic antibody response against HER-2/neu.
HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US7.0 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase Ib study in gastric cancer and the current stage of development is a Phase II study in gastric cancer.
Imugene’s M.D. & CEO, Ms Leslie Chong said, “Attaining the key US patent is an important milestone. This adds extra value to HER-Vaxx as this will protect it in the world’s largest pharmaceutical market until 2036.”
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs
and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno -oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.